Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy

PartnershipHM17321Positive

AI Analysis

Summary

Hanmi Pharmaceutical signed an exclusive licensing deal with Genentech for HM17321, a UCN2 analog for chronic weight management and obesity treatment, valued at up to $2.3 billion including upfront payments, milestones, and tiered royalties.

Importance:7/10

Sentiment:

0.80

licensingpartnershipobesityweight managementUCN2 analogHanmi PharmaceuticalGenentech

Related Companies

$HNMHF

Read the original article

Published by PR Newswire Biotech on August 24, 2026 4:40 AM

Read Original